• Stoke Therapeutics General Counsel, Corporate Secretary Jonathan Allan sold 1,457 common shares on June 16, 2026 at USD 29.95.
• Allan held 18,086 shares following the sale.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001966716-26-000010), on June 18, 2026, and is solely responsible for the information contained therein.